Humana Exceeds Quarterly Earnings Estimates with Stable Medical Costs
Humana reported second-quarter results that exceeded earnings estimates as medical and pharmacy cost trends aligned with expectations. The company maintained its long-term adjusted profit outlook of at least $9 per share by 2026, citing stable performance across new and existing members. CFO Celeste Mellet noted favorable inpatient costs among value-based providers but acknowledged elevated pharmacy expenses due to rising drug prices. Despite the strong earnings beat—$7.61 per share versus an expected $7.22—and revenue of $40.87 billion, shares fell over 4% premarket as analysts at Cantor Fitzgerald viewed the unchanged profit outlook as a disappointment compared to recent industry trends. Humana's medical benefit ratio came in at 91.2%, slightly higher than last year’s 89.9%, indicating stable but less favorable cost management. The results reflect broader challenges for Medicare Advantage insurers, including post-pandemic demand and high-cost drugs like GLP-1s. However, Humana's performance suggests it is managing these pressures better than some peers.
Tickers: $HUM
Topics: Earnings Healthcare Medicare Advantage